Chemotherapy Market Insights, 2006-2016
Overview
In a market currently valued around US$42 billion, cancer chemotherapies are on course for staggering growth potential and may revolutionize cancer treatments over the next 10 years. The chemotherapy market is currently the fastest growing in the pharmaceutical industry, driven by the explosion of potential therapeutic targets revealed by the molecular genetic assessments of cancer biology and fuelled by the magnitude of the disease worldwide, which shows every indication of increased incidence and sustained mortality rates over the next decade.
With more than 25 million people affected by cancer globally, and an estimated 5 million people dying each year as a result of cancer, new treatments are clearly needed to curtail these high mortality statistics despite the availability of effective cancer drugs such as Herceptin and Avastin. However although there are very exciting and promising novel cancer therapeutics on the horizon with limitless potential, enthusiasm must be tempered by the need to identify those chemotherapy approaches that may have the greatest potential for therapeutic success and suggests that there is a need to distinguish important new entries to the cancer therapeutics market from those therapy approaches that may not fare as well on the world market.
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities, provides an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological, and healthcare data, R&D programs, and innovating companies and products. The reader will benefit from authoritative critical review, market forecasts to 2016, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate research and industrial growth, and create new market opportunities.
Report Highlights and Key Findings
- Critical assessment of the challenges to the development of better, more efficacious cancer treatments with fewer side effects
- Analysis of the problems associated with the use of traditional cancer therapeutics, eg. drug resistance, lack of clinical efficacy, side effects
- Focused analysis of the global prevalence of cancer: incidence, mortality and survival rates as they relate to new directions in cancer research
- Identification of the major classes of cancer drugs currently in research and development using the newest technologies and genetic approaches
- Highlights the most successful cancer therapeutics that may serve as prototypes for the research and development of more effective drugs
Table of Contents
- Table of Contents
- Chapter 1. Introduction to Cancer: Epidemiology, Pathophysiology, Diagnosis, and Treatment
- Cancer Epidemiology
- Global Epidemiology of Cancer
- Global Statistics (World Health Organization - WHO)
- Cancer Incidence and Mortality by Geographical Regions Worldwide
- Cancer Epidemiology, United Kingdom (Office of National Statistics)
- Cancer Incidence and Mortality
- United Kingdom: Current Incidence Trends
- Incidence by Age Group, United Kingdom
- Current Mortality Trends in the United Kingdom
- Survival Trends for Most Common Cancers in the United Kingdom
- Current Cancer Statistics in the United States - American Cancer Society and
- Surveillance, Epidemiology and End Results Program (SEER)
- Current Incidence and Mortality Rates for the Most Common Cancers in the United States
- Current Cancer Estimates in the United States, 2005
- Incidence and Mortality Rates by Racial Group, United States
- Aetiology, Pathophysiology, and Diagnosis of Cancer by Type: Europe, United Kingdom and United States
- Lung Cancer
- Aetiology of Lung Cancer
- Risk Factors for Lung Cancer
- Pathophysiology of Lung Cancer
- Diagnosis of Lung Cancer
- Treatment of Lung Cancer
- Lung Cancer: Outcome
- Colorectal Cancer
- Aetiology and Pathophysiology
- Risk Factors for Colon Cancer
- Diagnosis of Colon Cancer
- Treatment of Colon Cancer
- Colon Cancer: Outcome
- Breast Cancer
- Aetiology of Breast Cancer
- Risk Factors for Breast Cancer
- Pathophysiology of Breast Cancer
- Diagnosis of Breast Cancer
- Treatment of Breast Cancer
- Breast Cancer: Outcome
- Prostate Cancer
- Aetiology of Prostate Cancer
- Pathophysiology of Prostate Cancer
- Diagnosis of Prostate Cancer
- Treatment of Prostate Cancer
- Prostate Cancer: Outcome
- Incidence and Mortality Rates for Other Common Cancers: Europe, and
- North America
- Cancer Staging and Grading: Diagnostic and Therapeutic Criteria
- Common Solid Tumour Malignancies
- Chemotherapy for Leukaemias and Lymphomas: Standard Treatment Options
- Leukaemias
- Lymphomas
- Chapter 2. Drug Development Challenges
- Tumour Biology
- Important Discoveries in Tumour Biology: Viruses, Genes and Cancer
- Cancer Genetics
- Towards a Model on the Genetic Origins of Cancer
- Pharmacology
- Pharmacology of the Important Groups of Chemotherapeutic Drugs Used in the
- Treatment of Cancer
- Mechanism of Action of Major Groups Chemotherapy Drugs and Treatment Applications
- Antimetabolites
- Antibiotics
- Alkylating Agents
- Vinca Alkaloids
- Other Alkaloids
- Platinum Compounds
- Treatment Resistance
- General Parameters of Drug Resistance
- Pharmacological Parameters of Chemosensitivity - Drug Delivery Applications
- Genetic Components of Drug Resistance Mechanisms
- Acquired Drug Resistance Mechanisms
- Current Biological and Pharmacological Obstacles to the Successful Treatment
- of Cancer
- Biological Complexity
- Pharmacological Challenges
- New Research/Technologies
- Gene-Targeted Therapeutic Approaches
- Angiogenesis
- Apoptosis
- Application of New Technologies to Chemotherapy Research and Development
- Chapter 3. Chemotherapeutic Treatment Options: Clinical Management and Drug Development Issues
- Current Chemotherapies
- Chemotherapy Treatment Overview
- Treatment Options
- Clinical Assessment of Solid Tumours
- Organ-Specific Chemotherapy
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Ovarian Cancer
- Testicular Cancer
- Cancers of Haematopoetic Origin - The Leukaemias
- Leukaemias
- Hodgkin’s Disease
- Non-Hodgkin’s Lymphoma
- Chemotherapy Drugs Approved by the United States Food and Drug Administration
- Chemotherapy Side Effects
- Clinical Treatment Administration Protocols
- Chemotherapy Drugs and Market Opportunities
- Chemotherapy Drug Reformulation
- Novel Drug Delivery Systems
- Chapter 4. The Market for Cancer Chemotherapies
- The Market for Chemotherapies
- The Global Cancer Market: Trends, Estimates, Economics, and Outlook
- Cancer Market: Overview
- Best-Selling Oncology Products
- Pharmaceutical Product Growth in Oncology
- Licensing and Chemotherapy Products
- Cancer Treatments and Pharmacoeconomics
- Critical Factors Affecting the High Pricing of Patented Cancer Drugs
- Generic Erosion
- High Costs of the New Super Drugs
- Healthcare Costs: United States
- Prescription Drug Costs and Coverage
- Healthcare Reimbursement Issues: United States
- Local Community Health Services
- Private Sector Health Programs: Managed Care
- Healthcare Purchasing Cooperatives: Federal Employers Health Benefits Program
- Uninsured Americans
- Current Issues in United States Healthcare Policy
- Healthcare Policies: United Kingdom
- National Health Service/National Institute for Health and Clinical Excellence
- Healthcare Policies: United States versus United Kingdom
- Healthcare Costs: Europe
- Future Trends in the Cancer Market Based on Cancer Incidence
- General Assessment of Future Trends in Cancer Therapeutics
- Cancer Incidence, Survival and Mortality Rates: General Trends
- Future Trends Based on Successful Treatment Approaches
- General Considerations
- Market Outlook for New Cancer Drugs
- Current Chemotherapies: Product Review and Commercial Outlook
- Genentech/Roche: Newly Approved Cancer Drug
- Avastin
- Tarceva
- Rituxan
- Herceptin
- Genentech Bio-Oncology Market Data: 2004-2005
- Roche
- American Pharmaceutical Partners: Abraxane
- MGI Pharma/Guildford Pharmaceuticals: Aloxi/Gliadel Wafer
- Sanofi-Aventis: Taxotere/Eloxatin
- Pfizer
- Aromasin
- Other Drugs in Pfizer’s Portfolio
- AstraZeneca
- Arimidex
- Faslodex
- Zoladex
- Iressa
- Novartis
- Gleevec
- Zometa
- Sandostatin
- Femara
- Schering-Plough
- Temodar
- Intron A
- GlaxoSmithKline
- Zofra
- Hycamtin
- Bexxar
- Arranon
- Genzyme
- Clolar
- Thyrogen
- Imclone: Erbitux
- 3M Pharmaceuticals: Aldara
- Supportive Therapies
- MGI Pharma
- Other Support Therapies
- Cancer Market Outlook: Summary
- Chapter 5. Chemotherapies in Research and Development
- General Trends in Global Oncology Markets Considered to Impact Chemotherapies
- in Research and Development
- Important Therapeutic Areas Targeted for Research and Development
- Promising New Oncology Drugs Poised for Market Entry
- Therapeutic Clinical Oncology Candidates: Product Review
- Cancer Vaccines: Gardasil (Merck) and Cervarix (GlaxoSmithKline)
- Sutent – Pfizer
- Sorafenib (BAY43-9006) - Bayer/Onyx
- Panitumamab - Amgen/Abgenix
- Prospective Oncology Drugs in Research and Development: Challenges for
- Drug Development
- Promising Cancer Drugs in Late-Stage Clinical Trials
- GlaxoSmithKline (GSK): Pipeline Products in Late-Stage Development
- Tykerb (Lapatinib)
- Eltrombopag
- Casopitant
- Novartis
- Femara
- PTKZK
- Introgen Therapeutics: Advexin
- United Therapeutics: OvaRex
- GPC Biotech AG: Satraplatin
- Cell Therapeutics: Xyotax
- NeoPharm: LEP-ETU
- Genta Pharmaceuticals: Genasense
- SuperGen: Orathecin
- Dendreon: Provenge
- Bayer: Sorafenib
- Promising Oncology Portfolios in Clinical Development
- GlaxoSmithKline
- Iboctadekin
- Vestipitant
- Ispenesib
- Pazopanib
- Relacatib
- Elacridar
- Novartis
- RAD001
- Patupilone
- PKC412
- ST1571
- Gimatecan
- AMN107
- AEE788
- INGN225
- INGN241
- INGN401
- Eisai
- Phase-III Products
- Phase-II Products
- Phase-I Products
- Abbott Laboratories
- Xinlay (Atrasentan)
- Merck
- SAHA
- Promising Biopharmaceutical Oncology Products in Clinical Development
- Market Outlook for New Oncology Products in Late-Stage Development
- Chapter 6: Cancer Research - Evaluating Drug Development and Market Opportunities
- Current Themes and Trends in Cancer Research
- Cancer Therapeutic Approaches in Research and Development
- Supportive Therapies
- Stem Cell Therapy
- Immunotherapy
- Emerging Biotechnologies
- Recombinant Vaccines
- Antisense Technology
- Humanized Monoclonal Antibodies
- Gene Therapy
- Nanoparticle Technology
- Current Biotechnological Cancer Therapeutic Approaches
- Therapeutic Cellular Vaccines
- Antigen/Adjuvant Vaccines
- Whole Tumour Vaccines
- Viral Vectors and DNA Vaccines
- Idiotype Vaccines
- Dendritophages
- Molecular Targets of Therapeutic Vaccines
- Therapeutic Vaccines in Clinical Trials
- Passive Immunotherapy: Monoclonal Antibodies
- Therapeutic Classes of Monoclonal Antibodies
- Anti-CD20 Monoclonal Antibodies
- Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies
- Cell Death Targets
- Small Molecule Targeted Anticancer Agents
- Promising Small Molecule Therapeutic Targets in Research and Development
- Tyrosine Kinase Inhibitors
- Heterodimerization Inhibitors
- STAT-3 Inhibitors
- Cyclin-Dependent Kinase Inhibitors
- Apoptosis Inducers
- Hypoxia Inducible Factor-1 Pathway
- Dipeptidyl Peptidase Inhibitors
- Small Molecule Therapies for Cancer Cachexia
- Small Molecule Immunostimulatory Agents
- Small Molecule Adhesion Targets
- Small Molecule Inhibitors: Resistance Mechanisms
- New Chemical Entities - Standard Chemotherapy Approaches
- New Investigative and Experimental Oncology Products
- Novel Oncology Products: Nontargeted Experimental and Investigational Agents
- Novel Drug Delivery Approaches in Research and Development
- Novel Molecular Tumour Targets in Research and Development
- Antisense Therapeutics
- Novel Treatment Approaches in Early Preclinical Stages of Development
- General Experimental Approaches
- Chemopreventive Approaches
- Development Outlook for Investigative/Experimental Oncology Products
- General Considerations
- Comparison of Therapeutic Treatment Modalities
- Standard Chemotherapy
- Small Molecule Inhibitors
- Monoclonal Antibodies
- Therapeutic Vaccines
- Novel Treatment Delivery Approaches
- Antisense Technologies
- Chapter 7. Companies Developing Cancer Drugs
- Leading Companies and Oncology Pipelines
- Leading Multinational Companies and Oncology Products
- Roche/Genentech
- Novartis
- Sanofi-Aventis
- AstraZeneca
- Eli Lilly
- GlaxoSmithKline
- Pfizer
- Bristol-Myers Squibb
- Schering-Plough
- Johnson & Johnson
- Other Oncology Focused Multinationals with Promising Pipelines
- Abbott Laboratories/TAP Pharmaceutical
- Merck & Co.
- Takeda
- Wyeth
- Leading Biopharmaceutical Companies and Oncology Therapeutics
- Amgen
- Genentech
- Genzyme
- Serono
- Medimmune
- Chiron
- Millennium Pharmaceuticals
- Specialty Oncology Drug Discovery and Development Companies
- Antigenics
- Antisoma
- Celgene
- Cell Therapeutics
- Ecopia Pharmaceutical Company
- Helix Biopharma
- ImClone Systems
- Immunogen
- Immusol
- Inovio
- Kosan Biosciences
- MediGene
- Milagen
- MorphoSys
- Myriad Pharmaceuticals
- NeoRx
- Protherics
- Receptor Biologix
- Regeneron Pharmaceuticals
- Starpharma
- Syrrx
- U3 Pharma
- Vertex Pharmaceuticals
- Viventia Biotech
- Xoma
- Zymo Genetics
- Other Discovery and Development Companies Specializing in Oncology Therapeutics
- Reference Sources
- List of Tables
- Table 1.1 Highest Mortality Rates for Common Cancers
- Table 1.2 Common Cancers in the United Kingdom Relative to Gender, 2004
- Table 1.3 Incidence Trends for the Common Cancers in the United Kingdom (1990-2001)
- Table 1.4 Mortality Rates in the United Kingdom, 2003
- Table 1.5 Changes in 5- and 10-Year Survival Rates for Common Cancers, United Kingdom (1971-1999 Diagnosis)
- Table 1.6 Incidence Rates for Common Cancers in the United States and United Kingdom
- Table 1.7 Incidence and Mortality for Most Prevalent Cancer in the United States, 2005 Estimates for Men and Women
- Table 1.8 Trends in Cancer Incidence, 2005 (% Total New Cases)
- Table 1.9 Incidence, Mortality, Survival Trends, and Risk Factors for 10 Less Common Cancers in the United States
- Table 1.10 Chemotherapy Options for Common Solid Tumour Malignancies by Disease Stage
- Table 2.1 Viruses Implicated in Human Cancers
- Table 2.2 Genes Most Commonly Identified in Human Cancers
- Table 2.3 Genes Most Commonly Implicated in Major Human Cancers
- Table 2.4 Chemotherapy Drugs Most Commonly Used to Treat Cancer
- Table 3.1 General Staging Criteria Relevant to Chemotherapy Treatment Options in Solid Tumour Malignancies
- Table 3.2 Chemotherapy Drugs Most Commonly Used to Treat Lung Cancer
- Table 3.3 Most Common Treatment Options for Limited Small Cell Lung Carcinoma
- Table 3.4 Most Common Treatment Options for Extensive Small Cell Lung Carcinoma
- Table 3.5 Less Common Treatment Protocols for Extensive Small Cell Lung Carcinoma
- Table 3.6 Most Common Treatment Protocols for Nonsmall Cell Lung Carcinoma
- Table 3.7 Experimental Chemotherapy for Advanced Lung Cancer
- Table 3.8 Chemotherapy Drugs Most Commonly Used to Treat Colorectal Cancer
- Table 3.9 Breast Cancer Chemotherapy Treatment Options
- Table 3.10 Hormonal Therapies Used in the Treatment of Advanced Prostate Cancer
- Table 3.11 Chemotherapy Drugs Most Commonly Used to Treat Ovarian Cancer
- Table 3.12 Second-Line Treatments for Ovarian Cancer
- Table 3.13 First-Line Combined Treatment Options for Advanced Ovarian Cancer
- Table 3.14 Second-Line Combined Treatment Options for Resistant Ovarian Cancer
- Table 3.15 Combined Chemotherapy Treatment Protocols for Acute Myeloid Leukaemia
- Table 3.16 Common Drugs Used to Treat Chronic Myeloid Leukaemia
- Table 3.17 Standard Treatment Options for Chronic Lymphocytic Leukaemia
- Table 3.18 Standard Treatment Options for Hodgkin’s Disease
- Table 3.19 Treatment Options for Advanced Low-Grade Non-Hodgkin’s Lymphoma
- Table 3.20 Treatment Options for Early-Stage Fast-Growing Non-Hodgkin’s Lymphoma
- Table 3.21 Chemotherapy Drugs Approved by the United States Food and Drug Administration
- Table 3.22 Drugs Administered to Combat Dose-Limiting Side Effects of Chemotherapy
- Table 4.1 Estimated Global Sales (US$) and Forecasts of Leading Cancer Chemotherapies, 2005-2016
- Table 4.2 Approximate 2004 Expenditures for Chemotherapy Treatment of the Most Common Cancers Based on Incidence Rates
- Table 4.3 Comparative Assessment of Positive Outcomes and Problems in Healthcare Systems, United States/United Kingdom
- Table 4.4 Accessibilty Ratings to New Cancer Drugs in Europe by Country
- Table 4.5 Global Incidence and Mortality Ratios for the Most Common Cancers by Gender
- Table 4.6 Global Incidence of Cancer by Site, Males and Females
- Table 4.7 Estimated Percentage of Cancer Cases by Type in Men and Women, United States, 2005
- Table 4.8 Predicted Average Lifetime Risk for Developing Cancer in Men and Women, 1999-2001 Estimates
- Table 4.9 Five-Year Relative Survival Rates for the Most Common Cancers, United States, 1995-2000
- Table 4.10 Comparison of 5-Year Survival Rates (%) for Most Common Cancers Over Three Time Periods, United States
- Table 4.11 Death Rates from the Most Common Cancers in Men and Women, United States, 2005 Estimates
- Table 4.12 New Anticancer Drugs with Strong Commercial Outlook Based on Clinical Efficacy
- Table 5.1 New Drug Application Submissions (Oncology), United States Food and Drug Administration, 2005
- Table 5.2 Comparison of Angiogenesis Inhibitors
- Table 5.3 Major Projected Competitors: Oncology Drugs for Advanced Colon Cancer that Target Growth Factor Signal Pathways
- Table 5.4 Tykerb: Summary of Clinical Trial Studies
- Table 5.5 Late-Stage Oncology Products in Clinical Development Grouped by Mechanism of Action
- Table 5.6 GlaxoSmithKline’s Portfolio of Oncology Products in Research and Development
- Table 5.7 Histone Deacetylase Inhibitors in Clinical Trials, 2006
- Table 5.8 Biotechnological Oncology Products in Clinical Development by Clinical Phase
- Table 5.9 Top Prospects for Market Success in the Oncology Pipeline
- Table 6.1 United States Federal Drug Administration Approved and Investigational Monoclonal Antibody Therapeutics for Cancer
- Table 6.2 Small Molecule Cancer Therapeutics in Research and Development by Clinical Phase
- Table 6.3 Novel Druggable Tumour Targets in Research and Development
- Table 6.4 Antisense Therapeutics in Research and Development
- Table 7.1 The Top 50 Global Pharmaceutical Companies (2004 and 2005 Revenues)
- Table 7.2 Global Portfolio Revenues and Market Share of Cancer Chemotherapies, 2005 (US$m)
- Table 7.3 Roche`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.4 Novartis` Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.5 Sanofi-Aventis` Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.6 AstraZeneca`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.7 Eli Lilly’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.8 GlaxoSmithKline`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.9 Pfizer`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.10 Bristol-Myers Squibb`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.11 Schering-Plough`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.12 Johnson & Johnson`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.13 Amgen`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.14 Genentech`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
- Table 7.15 Additional Discovery and Development Companies Specializing in Oncology Therapeutics
- List of Figures
- Figure 1.1 Total Cancer Mortality (Age Standardized Rates)
- Figure 1.2 Total Cancer Incidence (Age Standardized Rates)
- Figure 1.3 Averaged Incidence of the Most Common Cancers in the United Kingdom for Men and Women
- Figure 1.4 Incidence and Mortality of the 10 Most Common Cancers in the United States, 2005 Estimates
- Figure 1.5 Lung Cancer Incidence (Age Standardized Rates)
- Figure 1.6 Colon Cancer Incidence (Age Standardized Rates)
- Figure 1.7 Breast Cancer Incidence/Mortality (Age Standardized Rates)
- Figure 1.8 Prostate Cancer Incidence/Mortality (Age Standardized Rates)
- Figure 1.9 Bladder Cancer Incidence (Age Standardized Rates)
- Figure 1.10 Stomach Cancer Incidence (Age Standardized Rates)
- Figure 1.11 Cervical Cancer Incidence/Mortality (Age Standardized Rates)
- Figure 1.12 Melanoma Incidence (Age Standardized Rates)
- Figure 1.13 Larynx Cancer Incidence (Age Standardized Rates)
- Figure 1.14 Hodgkin’s Disease Incidence (Age Standardized Rates)
- Figure 1.15 Non-Hodgkin’s Lymphoma Incidence (Age Standardized Rates)
- Figure 1.16 Ovarian Cancer Incidence/Mortality (Age Standardized Rates)
- Figure 1.17 Chemotherapy Regimens Used to Treat Non-Hodgkin’s Lymphoma
- Figure 2.1 Origins of Chemotherapy Resistance
- Figure 2.2 Pharmacological Parameters of Drug Resistance
- Figure 2.3 Proliferative Cell Cycle: Genes and Drug Targets
- Figure 3.1 Factors Associated with Successful Chemotherapy Outcome
- Figure 4.1 Best-Selling Chemotherapies, 2005 (US$m)
- Figure 4.2 Market Share of the Top 10 Cancer Chemotherapies, 2005 & 2010
- Figure 4.3 Growth Rates of Best-Selling Cancer Chemotherapy Drugs, 2005
- Figure 4.4 Total Healthcare Costs: % Gross Domestic Product (GDP) by Country (2002)
- Figure 4.5 Key Parameters of Cancer Drug Market
- Figure 5.1 Therapeutic Classes of Oncology Drugs in the Product Pipeline
- Figure 6.1 General Clinical Research Areas in Cancer Therapeutics
- Figure 6.2 General Categories Of Therapeutic Enhancement Approaches
- Figure 6.3 Biotechnology Approaches to Cancer Therapeutic Research and Development
- Figure 6.4 Types of Therapeutic Cancer Vaccines in Clinical Research and Development
- Figure 6.5 Tumour Antigen Targets Used in the Development of Therapeutic Cancer Vaccines
- Figure 6.6 Monoclonal Antibody Therapeutic Targets
- Figure 6.7 Small Molecule Therapy Targets
- Figure 6.8 Combined Chemotherapy Treatment Possibilities
- Figure 6.9 Cell Targets of Experimental Cancer Therapeutics: Drugs and Delivery Mode
- Figure 7.1 Leading Oncology Companies by Chemotherapy Portfolio Revenues, 2005 (US$m)
Other users found this report page using the following search terms: chemotherapy cytotoxic chemotherapy market cancer statistics europe oncology drug global panitumamab drugs
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.